Vericel Corporation (VCEL) earnings
VCEL earnings moved a median of -0.69% by the close. Quarterly and annual VCEL reports and results, each read against the price at its own news timestamp. Back to the VCEL overview →
31 measured VCEL earnings events.
Where these VCEL earnings landedvs 31 measured VCEL earnings reactions
| Middle 50% of VCEL earnings reactions | -4.14% to +1.93% |
|---|---|
| Median reaction (to close) | -0.69% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 VCEL earnings events with a measured close landed between -4.14% and +1.93%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Vericel Corp For: Jun 30 | SEC filing · Form 10-Q | -1.30% | -2.64% | |
| Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | Press release | -1.30% | -2.64% | |
| Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026 | Press release | +0.11% | +1.25% | |
| Form 10-Q Vericel Corp For: Mar 31 | SEC filing · Form 10-Q | -8.39% | -13.26% | |
| Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Press release | -8.39% | -13.26% | |
| Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026 | Press release | +0.75% | -0.17% | |
| Form 10-K Vericel Corp For: Dec 31 | SEC filing · Form 10-K | -0.03% | +0.99% | |
| Form 10-Q Vericel Corp For: Sep 30 | SEC filing · Form 10-Q | -3.10% | -6.90% | |
| Vericel Reports Third Quarter 2025 Financial Results | Press release | -3.10% | -6.90% | |
| Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 | Press release | +1.96% | -0.69% | |
| Form 10-Q Vericel Corp For: Jun 30 | SEC filing · Form 10-Q | -0.92% | -5.52% | |
| Vericel Reports Second Quarter 2025 Financial Results | Press release | -0.92% | -5.52% | |
| Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 | Press release | +0.29% | -2.76% | |
| Form 10-Q Vericel Corp For: Mar 31 | SEC filing · Form 10-Q | -2.57% | +4.03% | |
| Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance | Press release | -2.57% | +4.03% | |
| Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 | Press release | -0.31% | +2.24% | |
| Form 10-K Vericel Corp For: Dec 31 | SEC filing · Form 10-K | -0.97% | -9.50% | |
| Form 10-Q Vericel Corp For: Sep 30 | SEC filing · Form 10-Q | +0.10% | +1.63% | |
| Vericel Reports Third Quarter 2024 Financial Results | Press release | +0.10% | +1.63% | |
| Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 | Press release | -0.47% | +0.94% | |
| Form 10-Q Vericel Corp For: Jun 30 | SEC filing · Form 10-Q | -4.45% | -2.08% | |
| Vericel Reports Second Quarter 2024 Financial Results | Press release | -4.45% | -2.08% | |
| Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 | Press release | -0.52% | -0.39% | |
| Form 10-Q Vericel Corp For: Mar 31 | SEC filing · Form 10-Q | +1.99% | +3.67% | |
| Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance | Press release | +1.99% | +3.67% | |
| Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 | Press release | +0.60% | -0.86% | |
| Form 10-K Vericel Corp For: Dec 31 | SEC filing · Form 10-K | +1.18% | -7.21% | |
| Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results | Press release | +0.91% | +6.14% | |
| Form 10-Q Vericel Corp For: Sep 30 | SEC filing · Form 10-Q | +0.03% | +3.92% | |
| Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance | Press release | +0.03% | +3.92% | |
| Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023 | Press release | -0.49% | -1.35% |
Keep exploring
More VCEL: analyst actions → · SEC filings → · VCEL overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ALLIQUA BIOMEDICAL (ALQA) | 407 | -0.11% | 43% |
| NeoGenomics, Inc. (NEO) | 406 | -0.22% | 44% |
| SPRING BANK PHARMACEUTICALS (SBPH) | 404 | 0.00% | 37% |
| AKCEA THERAPEUTICS (AKCA) | 401 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.